NN 9041
Alternative Names: DNA immunotherapy - Novo Nordisk; NN-9041; Type 1 diabetes therapeutic - Novo NordiskLatest Information Update: 15 Sep 2022
At a glance
- Originator Novo Nordisk
- Class Antihyperglycaemics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Type 1 diabetes mellitus
Most Recent Events
- 31 Dec 2021 Phase-I clinical trials in Type 1 diabetes mellitus in Denmark (unspecified route)